Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions

state of the art

Authors

  • Habib Yaribeygi Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran https://orcid.org/0000-0002-1706-6212
  • Mina Maleki Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran https://orcid.org/0000-0003-4723-3058
  • Alexandra E. Butler Research Department, Royal College of Surgeons in Ireland Bahrain, Adliya, 15503, Bahrain https://orcid.org/0000-0002-5762-3917
  • Tannaz Jamialahamdi Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran https://orcid.org/0000-0001-9521-3153
  • Amirhossein Sahebkar Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. E-mail: amir_saheb2000@yahoo.com; sahebkara@mums.ac.ir https://orcid.org/0000-0002-8656-1444

DOI:

https://doi.org/10.17179/excli2022-5482

Keywords:

sodium-glucose cotransporter 2 inhibitors, mitochondria, diabetes mellitus, mitophagy, oxidative stress

Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are a class of newly introduced antidiabetic drugs with potent hypoglycemic effects. Recent evidence suggests that these drugs have extraglycemic impacts and are therefore able to provide additional benefits beyond glucose lowering. Mitochondrial dysfunction is a central facet of many disorders that negatively impacts many tissues and organs, especially in the setting of diabetes. Therefore, it would be hugely beneficial if an antidiabetic drug could also provide mitochondrial benefits to improve cellular function and reduce the risk of diabetic complications. In this review, we have surveyed the literature for possible mitochondrial benefits of SGLT2is and we discuss the possible mechanisms involved.

Downloads

Published

2023-01-04

How to Cite

Yaribeygi, H., Maleki, M., Butler, A. E., Jamialahamdi, T., & Sahebkar, A. (2023). Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions: state of the art . EXCLI Journal, 22, 53–66. https://doi.org/10.17179/excli2022-5482

Issue

Vol. 22 (2023)

Section

Review articles

Categories

License

Copyright (c) 2023 Habib Yaribeygi, Mina Maleki, Alexandra E. Butler, Tannaz Jamialahamdi, Amirhossein Sahebkar

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish in this journal agree to the following terms:

  • The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
  • The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
  • Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
  • The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).

Most read articles by the same author(s)

<< < 1 2